Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label Safety and Pharmacokinetic Study of Single (TDF), Dual (TDF-FTC), and Triple ARV IVR (TDF-FTC-MVC) in Healthy Women

Next Previous
X
Search
Trial Profile

Open-Label Safety and Pharmacokinetic Study of Single (TDF), Dual (TDF-FTC), and Triple ARV IVR (TDF-FTC-MVC) in Healthy Women

Status: Completed
Phase of Trial: Phase 0

Latest Information Update: 04 Jul 2019

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Emtricitabine/maraviroc/tenofovir-disoproxil-fumarate (Primary) ; Emtricitabine/tenofovir disoproxil maleate (Primary) ; Tenofovir disoproxil fumarate (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Auritec Pharmaceuticals

    • Most Recent Events

    • 30 Jan 2017 Status changed from recruiting to completed.
    • 04 Mar 2016 Planned End Date changed from 1 Jul 2016 to 1 Sep 2016 as reported by ClinicalTrials.gov.
    • 04 Mar 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Jun 2016 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top